About DearMamma
DearMamma is a company based in Affoltern Am Albis (Switzerland) founded in 2006 by Sonja Dinner. It operates as a B2C. DearMamma operates in a competitive market with competitors including Resilience, The Blue Box, MyBCTeam, Breast Advocate and Aware, among others.
- Headquarter Affoltern Am Albis, Switzerland
- Founders Sonja Dinner
- SectorsHealthcare
- Website dearmamma.org
- Social X Facebook Instagram
Apps and channels of DearMamma
DearMamma publishes 2 mobile apps with over 50K+ downloads.
People of DearMamma
1 people are tracked at DearMamma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Sonja Dinner | Founder, President | Leadership |
Complete people profiles for DearMamma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of DearMamma
DearMamma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Resilience, The Blue Box, MyBCTeam, Breast Advocate and Aware, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| resilience.care | 2021 | Paris, France | $77M | – | A digital solution is provided for remote oncology monitoring. | |
| thebluebox.tech | 2020 | Irvine, United States | $4.06M | – | Breast cancer biomarkers are monitored via smart device and app. | |
| mybcteam.com | 2012 | San Francisco, United States | – | 55 | Social network providing support, information, and connections for breast cancer patients. | |
| breastadvocateapp.com | 2016 | San Antonio, United States | – | – | Offers evidence-based guidance on breast cancer surgery and reconstruction via app. | |
| xaware.net | 1999 | Colorado Springs, United States | $7.4M | – | Aware is focused on providing AI-driven design solutions and content. | |
| pinkdetect.com | 2023 | Toronto, Canada | – | – | App provides breast cancer risk assessments and self-exam guidance for women. | |
| myriskbreastcancer.com | 2021 | United States | – | – | Online platform for calculating personal breast cancer risk and guidelines. |
Detailed competitors of DearMamma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of DearMamma
The website of DearMamma (dearmamma.org) receives about 2.1K visits a month.
- Monthly visits2.1K
▲ 24.3% vs previous month
Similar companies to DearMamma
10 companies that operate in the same segment as DearMamma (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about DearMamma
DearMamma was founded in 2006.
DearMamma is headquartered in Affoltern Am Albis, Switzerland. It is registered at Affoltern Am Albis, Zurich, Switzerland.
DearMamma, founded in 2006 in Affoltern Am Albis, Switzerland, focuses on providing healthcare solutions, providing digital health services, medical apps, and cancer management. Provides an app with tools for managing breast cancer. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
DearMamma's top competitors include Resilience, The Blue Box and Aware.
Yes. DearMamma publishes DearMamma and 1 more app, with over 50,000 downloads.